Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.38 |
| ▸ | SELP | P16109 | 2/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | MAG | P20916 | 3/20 | 0.32 |
| ▸ | CD22 | P20273 | 1/20 | 0.31 |
| ▸ | IGF2R | P11717 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14823604 | 1.00 | SIGLEC7 (0.38) | SIGLEC7SELPSELLMAGCD22 | |
| SCHEMBL15965910 | 1.00 | SIGLEC7 (0.38) | SIGLEC7SELPSELLMAGCD22 | |
| SCHEMBL15965863 | 0.97 | SIGLEC7 (0.38) | SIGLEC7SELPSELLMAGCD22 | |
| SCHEMBL15965923 | 0.97 | SIGLEC7 (0.38) | SIGLEC7SELPSELLMAGCD22 | |
| SCHEMBL14823605 | 0.97 | SIGLEC7 (0.38) | SIGLEC7SELPSELLMAGCD22 | |
| SCHEMBL15965927 | 0.89 | SELL (0.35) | SIGLEC7SELPSELLMAGCD22 | |
| SCHEMBL15965934 | 0.86 | SELL (0.35) | SIGLEC7SELPSELLMAGCD22 | |
| SCHEMBL15966433 | 0.85 | SIGLEC7 (0.39) | SIGLEC7MAGIGF2R | |
| SCHEMBL15965870 | 0.85 | SIGLEC7 (0.40) | SIGLEC7SELPSELLMAGIGF2R | |
| SCHEMBL15965993 | 0.85 | SIGLEC7 (0.40) | SIGLEC7SELPSELLMAGIGF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140234364-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234364-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | FUT5, DAD1, STT3B | SIGLEC7 56/4885SELP 255/4885SELL 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.